Cassava and Anavex Shares Gain On Alzheimer Drug Trials

Shares of Cassava Sciences (NASDAQ: SAVA) and Anavex Life Sciences (NASDAQ: AVXL) are surging premarket on Thursday following Cassava’s announcement on Tuesday regarding positive data study of simufilam in Alzheimer’s disease.

Cassava reported that interim analysis from an open-label study into its lead drug candidate for treating Alzheimer’s disease showed improved patient cognition and behaviour following six months of treatment.

Fellow biotech developer Anavex Life Sciences is also gaining from Cassava’s news as it’s own lead asset, Anavex®2-73 is currently in phase 2b/3 trials in Alzheimer’s disease.

X testing X

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

The trial has enrolled 80% of patients with the full enrollment of 450 patients expected in early 2021.

Anavex shares were halted for volatility early in the morning and are currently trading over 59 per cent higher at $16.51.

Cassava’s stock price closed 141 per cent higher on Tuesday, following the simufilam announcement, and gained another 58 per cent on Wednesday. So far, premarket on Thursday its share price is up 37 per cent at $121 per share.